Gainers
- Regulus Therapeutics (NASDAQ:RGLS) stock increased by 12.4% to $1.45 during Thursday's after-market session. The company's market cap stands at $28.2 million.
- SeqLL (NASDAQ:SQL) shares moved upwards by 10.34% to $15.79. The company's market cap stands at $6.0 million.
- bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 9.43% to $1.16. The market value of their outstanding shares is at $10.1 million.
- Enveric Biosciences (NASDAQ:ENVB) shares increased by 9.05% to $2.65. The market value of their outstanding shares is at $5.7 million.
- Blue Water Biotech (NASDAQ:BWV) shares rose 8.67% to $0.61. Trading volume for this security closed at 129.4K, accounting for 130.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.7 million.
- China Pharma Holding (AMEX:CPHI) stock rose 7.01% to $0.14. At the close, China Pharma Holding's trading volume reached 65.8K shares. This is 7.2% of its average volume over the last 100 days. The company's market cap stands at $1.6 million.
Losers
- Baudax Bio (NASDAQ:BXRX) shares decreased by 10.1% to $0.31 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million.
- Surrozen (NASDAQ:SRZN) stock declined by 6.49% to $0.43. The market value of their outstanding shares is at $13.0 million.
- TransCode Therapeutics (NASDAQ:RNAZ) stock decreased by 6.45% to $0.65. Today's trading volume for this security ended up closing at 583.3K shares, which is 103.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.
- IGC Pharma (AMEX:IGC) stock fell 5.33% to $0.37. The market value of their outstanding shares is at $19.9 million.
- Taysha Gene Therapies (NASDAQ:TSHA) stock declined by 4.63% to $2.89. The market value of their outstanding shares is at $540.3 million.
- TRACON Pharma (NASDAQ:TCON) stock decreased by 4.57% to $0.21. The market value of their outstanding shares is at $6.4 million. See Also:
This article was generated by Benzinga's automated content engine and reviewed by an editor.